Physiomics plc (PYC) ORD GBP0.004
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Physiomics secures 'substantial new contract' with existing pharma client
18 March 2024 09:43
(Sharecast News) - Mathematical modelling and data science company Physiomics has been awarded "a substantial new contract" by an existing large pharmaceutical client.
-
Physiomics revenue rises, losses narrow in first half
7 March 2024 12:50
(Sharecast News) - Physiomics reported revenue of £0.37m in its interim results on Thursday, up from the £0.34m it recorded a year earlier.
-
Physiomics secures contract with University of Sheffield
19 February 2024 10:16
(Sharecast News) - Data science firm Physiomics has been chosen by the University of Sheffield to support a grant-funded project focused on an insect model of cancer treatment.
-
Physiomics awarded further contract by Numab Therapeutics
5 February 2024 10:01
(Sharecast News) - Data science company Physiomics said on Monday that it had been awarded a further contract by an existing client.
-
Physiomics receives Innovate UK funding grant
10 November 2023 08:14
(Sharecast News) - Computational biology firm Physiomics said on Friday that it had been awarded a grant by Innovate UK and the Office for Life Sciences as part of the UK Government's Advancing...
-
Physiomics inks contract extension with Numab Therapeutics
8 August 2023 15:49
(Sharecast News) - Mathematical modelling company Physiomics, which specialises in the development of oncology drugs and personalised medicine, confirmed a renewed contract with Numab Therapeutics on Tuesday.
-
Physiomics inks collaboration deal with ValiRx subsidiary
26 April 2023 13:17
(Sharecast News) - Physiomics announced on Wednesday that it has signed a collaborative services agreement with Inaphaea BioLabs - a wholly-owned subsidiary of ValiRx.
-
Physiomics to present work at US cancer research summit
14 April 2023 12:34
(Sharecast News) - Physiomics announced its participation in the American Association for Cancer Research (AACR) annual meeting on Friday, being held in Orlando on 14-19 April.
-
Physiomics wins further contract with Bicycle Therapeutics
10 March 2023 08:51
(Sharecast News) - Oncology consultancy Physiomics revealed on Friday that it had been awarded a further contract by existing client Bicycle Therapeutics.
-
Physiomics confident despite weaker first half
7 March 2023 17:05
(Sharecast News) - Oncology consultancy firm Physiomics reported revenue of £0.34m in its first half on Tuesday - a slight decrease from the £0.37m reported in the same period a year earlier.
-
Physiomics inks deal to work with Cancer Research UK
12 October 2022 12:42
(Sharecast News) - Modelling and simulation-focussed consultancy Physiomics that it has signed an agreement to work with Cancer Research UK, it announced on Wednesday.
-
Physiomics wins new contract with French pharma company
8 April 2022 09:13
(Sharecast News) - Oncology drug developer Physiomics has been awarded a contract by new client, the Servier Group, an international pharmaceutical company based in France.
Company announcements Announcements
-
Contract Award
18 March 2024 07:00
Physiomics
-
Interim Results
7 March 2024 07:00
Physiomics
-
Options Award
6 February 2024 07:00
Physiomics
-
Board Changes
22 January 2024 07:00
Physiomics
-
Result of AGM
21 November 2023 15:30
Physiomics
-
Innovate UK grant award
10 November 2023 07:00
Physiomics
-
Notice of AGM
18 October 2023 07:00
Physiomics
-
Change of Registered Office
4 October 2023 07:00
Physiomics
-
Annual Financial Report
28 September 2023 07:00
Physiomics
-
Senior Management Update
4 September 2023 07:00
Physiomics
-
Contract Award
31 August 2023 13:00
Physiomics
-
Director Dealing
25 July 2023 07:00
Physiomics
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.